The Experts below are selected from a list of 158826 Experts worldwide ranked by ideXlab platform
Jean-françois Chatal - One of the best experts on this subject based on the ideXlab platform.
-
Cyclotron-Based Radiopharmaceuticals for Nuclear Medicine Therapy
Therapeutic Nuclear Medicine, 2012Co-Authors: Jacques Barbet, Mickaël Bourgeois, Jean-françois ChatalAbstract:New radionuclides, used for targeted radionuclide therapy, can be produced by Cyclotrons dedicated to nuclear medicine and which have become common. Among beta particle emitting radionuclides, copper-67 has favorable physical and biochemical properties. Its halflife of 2.58 days is well matched to the pharmacokinetics of F(ab’)2 antibody fragments and the energy of emitted electrons corresponds to a short path length that fits the size of disseminated clusters of malignant cells. But production of this radionuclide requires a high energy/high intensity Cyclotron which limits its availability. Scandium-47 has favorable physical properties but also requires high proton energy Cyclotron which explains its poor availability. Among alpha-emitting radionuclides which seem to be optimal for killing of isolated tumor cells due to the short path length and high linear energy transfer (LET) of emitted alpha particles, astatine-211 has attracted much interest because of a longer half-life (7.2 h) than that of bismuth-213 or bismuth-212 which have also been tested in preclinical and clinical studies. Actinium-225 which can be produced by proton irradiation of radium-226 and bismuth-213 have been proposed years ago for targeted radionuclide therapy. Actinium-225 has been presented as an « atomic nanogenerator » due to a cascade of radioactive daughters emitting four alpha particles per actinium-225 atom. Bismuth-213 has been used one decade ago for labeling of a humanized anti-CD33 antibody in a phase I clinical study in patients with acute myelogenous antibody. Finally terbium-149 with a half-life of 4.1 h is another alternative alpha-emitting radionuclide and has been used in a few preclinical studies. Radionuclides which emit Auger electrons such as indium-111 may be highly toxic if delivered in or close to nucleus of tumor cells. Thus today there is a real need for production of innovative radionuclides by Cyclotrons to improve efficacy of targeted radionuclide therapy.
-
ARRONAX, a high-energy and high-intensity Cyclotron for nuclear medicine
European Journal of Nuclear Medicine and Molecular Imaging, 2008Co-Authors: Ferid Haddad, Jacques Barbet, L. Ferrer, Arnaud Guertin, T. Carlier, N. Michel, Jean-françois ChatalAbstract:Purpose This study was aimed at establishing a list of radionuclides of interest for nuclear medicine that can be produced in a high-intensity and high-energy Cyclotron. Methods We have considered both therapeutic and positron emission tomography radionuclides that can be produced using a high-energy and a high-intensity Cyclotron such as ARRONAX, which will be operating in Nantes (France) by the end of 2008. Novel radionuclides or radionuclides of current limited availability have been selected according to the following criteria: emission of positrons, low-energy beta or alpha particles, stable or short half-life daughters, half-life between 3 h and 10 days or generator-produced, favourable dosimetry, production from stable isotopes with reasonable cross sections. Results Three radionuclides appear well suited to targeted radionuclide therapy using beta (67Cu, 47Sc) or alpha (211At) particles. Positron emitters allowing dosimetry studies prior to radionuclide therapy (64Cu, 124I, 44Sc), or that can be generator-produced (82Rb, 68Ga) or providing the opportunity of a new imaging modality (44Sc) are considered to have a great interest at short term whereas 86Y, 52Fe, 55Co, 76Br or 89Zr are considered to have a potential interest at middle term. Conclusions Several radionuclides not currently used in routine nuclear medicine or not available in sufficient amount for clinical research have been selected for future production. High-energy, high-intensity Cyclotrons are necessary to produce some of the selected radionuclides and make possible future clinical developments in nuclear medicine. Associated with appropriate carriers, these radionuclides will respond to a maximum of unmet clinical needs.
Ferid Haddad - One of the best experts on this subject based on the ideXlab platform.
-
ARRONAX, a high-energy and high-intensity Cyclotron for nuclear medicine
European Journal of Nuclear Medicine and Molecular Imaging, 2008Co-Authors: Ferid Haddad, Jacques Barbet, L. Ferrer, Arnaud Guertin, T. Carlier, N. Michel, Jean-françois ChatalAbstract:Purpose This study was aimed at establishing a list of radionuclides of interest for nuclear medicine that can be produced in a high-intensity and high-energy Cyclotron. Methods We have considered both therapeutic and positron emission tomography radionuclides that can be produced using a high-energy and a high-intensity Cyclotron such as ARRONAX, which will be operating in Nantes (France) by the end of 2008. Novel radionuclides or radionuclides of current limited availability have been selected according to the following criteria: emission of positrons, low-energy beta or alpha particles, stable or short half-life daughters, half-life between 3 h and 10 days or generator-produced, favourable dosimetry, production from stable isotopes with reasonable cross sections. Results Three radionuclides appear well suited to targeted radionuclide therapy using beta (67Cu, 47Sc) or alpha (211At) particles. Positron emitters allowing dosimetry studies prior to radionuclide therapy (64Cu, 124I, 44Sc), or that can be generator-produced (82Rb, 68Ga) or providing the opportunity of a new imaging modality (44Sc) are considered to have a great interest at short term whereas 86Y, 52Fe, 55Co, 76Br or 89Zr are considered to have a potential interest at middle term. Conclusions Several radionuclides not currently used in routine nuclear medicine or not available in sufficient amount for clinical research have been selected for future production. High-energy, high-intensity Cyclotrons are necessary to produce some of the selected radionuclides and make possible future clinical developments in nuclear medicine. Associated with appropriate carriers, these radionuclides will respond to a maximum of unmet clinical needs.
Jacques Barbet - One of the best experts on this subject based on the ideXlab platform.
-
Cyclotron-Based Radiopharmaceuticals for Nuclear Medicine Therapy
Therapeutic Nuclear Medicine, 2012Co-Authors: Jacques Barbet, Mickaël Bourgeois, Jean-françois ChatalAbstract:New radionuclides, used for targeted radionuclide therapy, can be produced by Cyclotrons dedicated to nuclear medicine and which have become common. Among beta particle emitting radionuclides, copper-67 has favorable physical and biochemical properties. Its halflife of 2.58 days is well matched to the pharmacokinetics of F(ab’)2 antibody fragments and the energy of emitted electrons corresponds to a short path length that fits the size of disseminated clusters of malignant cells. But production of this radionuclide requires a high energy/high intensity Cyclotron which limits its availability. Scandium-47 has favorable physical properties but also requires high proton energy Cyclotron which explains its poor availability. Among alpha-emitting radionuclides which seem to be optimal for killing of isolated tumor cells due to the short path length and high linear energy transfer (LET) of emitted alpha particles, astatine-211 has attracted much interest because of a longer half-life (7.2 h) than that of bismuth-213 or bismuth-212 which have also been tested in preclinical and clinical studies. Actinium-225 which can be produced by proton irradiation of radium-226 and bismuth-213 have been proposed years ago for targeted radionuclide therapy. Actinium-225 has been presented as an « atomic nanogenerator » due to a cascade of radioactive daughters emitting four alpha particles per actinium-225 atom. Bismuth-213 has been used one decade ago for labeling of a humanized anti-CD33 antibody in a phase I clinical study in patients with acute myelogenous antibody. Finally terbium-149 with a half-life of 4.1 h is another alternative alpha-emitting radionuclide and has been used in a few preclinical studies. Radionuclides which emit Auger electrons such as indium-111 may be highly toxic if delivered in or close to nucleus of tumor cells. Thus today there is a real need for production of innovative radionuclides by Cyclotrons to improve efficacy of targeted radionuclide therapy.
-
ARRONAX, a high-energy and high-intensity Cyclotron for nuclear medicine
European Journal of Nuclear Medicine and Molecular Imaging, 2008Co-Authors: Ferid Haddad, Jacques Barbet, L. Ferrer, Arnaud Guertin, T. Carlier, N. Michel, Jean-françois ChatalAbstract:Purpose This study was aimed at establishing a list of radionuclides of interest for nuclear medicine that can be produced in a high-intensity and high-energy Cyclotron. Methods We have considered both therapeutic and positron emission tomography radionuclides that can be produced using a high-energy and a high-intensity Cyclotron such as ARRONAX, which will be operating in Nantes (France) by the end of 2008. Novel radionuclides or radionuclides of current limited availability have been selected according to the following criteria: emission of positrons, low-energy beta or alpha particles, stable or short half-life daughters, half-life between 3 h and 10 days or generator-produced, favourable dosimetry, production from stable isotopes with reasonable cross sections. Results Three radionuclides appear well suited to targeted radionuclide therapy using beta (67Cu, 47Sc) or alpha (211At) particles. Positron emitters allowing dosimetry studies prior to radionuclide therapy (64Cu, 124I, 44Sc), or that can be generator-produced (82Rb, 68Ga) or providing the opportunity of a new imaging modality (44Sc) are considered to have a great interest at short term whereas 86Y, 52Fe, 55Co, 76Br or 89Zr are considered to have a potential interest at middle term. Conclusions Several radionuclides not currently used in routine nuclear medicine or not available in sufficient amount for clinical research have been selected for future production. High-energy, high-intensity Cyclotrons are necessary to produce some of the selected radionuclides and make possible future clinical developments in nuclear medicine. Associated with appropriate carriers, these radionuclides will respond to a maximum of unmet clinical needs.
T. Carlier - One of the best experts on this subject based on the ideXlab platform.
-
ARRONAX, a high-energy and high-intensity Cyclotron for nuclear medicine
European Journal of Nuclear Medicine and Molecular Imaging, 2008Co-Authors: Ferid Haddad, Jacques Barbet, L. Ferrer, Arnaud Guertin, T. Carlier, N. Michel, Jean-françois ChatalAbstract:Purpose This study was aimed at establishing a list of radionuclides of interest for nuclear medicine that can be produced in a high-intensity and high-energy Cyclotron. Methods We have considered both therapeutic and positron emission tomography radionuclides that can be produced using a high-energy and a high-intensity Cyclotron such as ARRONAX, which will be operating in Nantes (France) by the end of 2008. Novel radionuclides or radionuclides of current limited availability have been selected according to the following criteria: emission of positrons, low-energy beta or alpha particles, stable or short half-life daughters, half-life between 3 h and 10 days or generator-produced, favourable dosimetry, production from stable isotopes with reasonable cross sections. Results Three radionuclides appear well suited to targeted radionuclide therapy using beta (67Cu, 47Sc) or alpha (211At) particles. Positron emitters allowing dosimetry studies prior to radionuclide therapy (64Cu, 124I, 44Sc), or that can be generator-produced (82Rb, 68Ga) or providing the opportunity of a new imaging modality (44Sc) are considered to have a great interest at short term whereas 86Y, 52Fe, 55Co, 76Br or 89Zr are considered to have a potential interest at middle term. Conclusions Several radionuclides not currently used in routine nuclear medicine or not available in sufficient amount for clinical research have been selected for future production. High-energy, high-intensity Cyclotrons are necessary to produce some of the selected radionuclides and make possible future clinical developments in nuclear medicine. Associated with appropriate carriers, these radionuclides will respond to a maximum of unmet clinical needs.
Arnaud Guertin - One of the best experts on this subject based on the ideXlab platform.
-
ARRONAX, a high-energy and high-intensity Cyclotron for nuclear medicine
European Journal of Nuclear Medicine and Molecular Imaging, 2008Co-Authors: Ferid Haddad, Jacques Barbet, L. Ferrer, Arnaud Guertin, T. Carlier, N. Michel, Jean-françois ChatalAbstract:Purpose This study was aimed at establishing a list of radionuclides of interest for nuclear medicine that can be produced in a high-intensity and high-energy Cyclotron. Methods We have considered both therapeutic and positron emission tomography radionuclides that can be produced using a high-energy and a high-intensity Cyclotron such as ARRONAX, which will be operating in Nantes (France) by the end of 2008. Novel radionuclides or radionuclides of current limited availability have been selected according to the following criteria: emission of positrons, low-energy beta or alpha particles, stable or short half-life daughters, half-life between 3 h and 10 days or generator-produced, favourable dosimetry, production from stable isotopes with reasonable cross sections. Results Three radionuclides appear well suited to targeted radionuclide therapy using beta (67Cu, 47Sc) or alpha (211At) particles. Positron emitters allowing dosimetry studies prior to radionuclide therapy (64Cu, 124I, 44Sc), or that can be generator-produced (82Rb, 68Ga) or providing the opportunity of a new imaging modality (44Sc) are considered to have a great interest at short term whereas 86Y, 52Fe, 55Co, 76Br or 89Zr are considered to have a potential interest at middle term. Conclusions Several radionuclides not currently used in routine nuclear medicine or not available in sufficient amount for clinical research have been selected for future production. High-energy, high-intensity Cyclotrons are necessary to produce some of the selected radionuclides and make possible future clinical developments in nuclear medicine. Associated with appropriate carriers, these radionuclides will respond to a maximum of unmet clinical needs.
